Brain, Mood & Sleep

DSIP / BPC-157 / CJC-1295

A nighttime protocol pairing sleep architecture support with tissue repair and growth hormone signaling.

Baseline Labs Generally RequiredInjectableLimited evidenceCompounded
  • Physician reviewed
  • 503A pharmacy compounded
  • Patient-specific prescription

Formats & pricing

  • combination vial — reconstituted injectable$240
Start my CareSee how it works

Pricing reflects the compounded preparation and physician review. Final therapy and dosing are determined only after your intake is reviewed.

Overview

What is DSIP / BPC-157 / CJC-1295?

This preparation targets the overnight recovery window — DSIP for sleep depth, BPC-157 for tissue repair, and CJC-1295 for growth hormone release, all of which are most active during sleep.

Mechanism

How it works

Growth hormone release peaks during slow-wave sleep, and tissue repair follows the same rhythm. The rationale for this stack is timing: each component works within the same nightly window.

Wellness support

Potential wellness support areas

These areas are commonly discussed within wellness-focused protocols. They are educational statements, not medical claims or guarantees of outcome.

  • Explored for sleep depth and overnight recovery
  • Discussed for body composition and repair
  • Potential support for daytime energy
  • Consolidated into a single nightly injection

Administration

Format & dosing

One subcutaneous injection nightly before bed. Your physician sets dosing and cycle length after intake review.

Labs & monitoring

Labs, testing & monitoring

Your physician determines the final testing requirements for DSIP / BPC-157 / CJC-1295 after reviewing your intake. The panels below are what is commonly reviewed for this therapy — they are educational guidance, not a fixed requirement.

Bloodwork status

Baseline Labs Generally Required

Commonly reviewed at baseline

  • IGF-1
  • Comprehensive metabolic panel (CMP)
  • Fasting glucose and A1c
  • Lipid panel
  • Thyroid panel (TSH, free T4)

Follow-up & monitoring

Because a growth hormone secretagogue is included, IGF-1 and glycemic markers are commonly rechecked at 8 to 12 weeks.

Who may not be a candidate

  • Pregnancy or nursing
  • Active malignancy without oncology clearance
  • Known hypersensitivity to the preparation
  • Untreated obstructive sleep apnea
  • Uncontrolled diabetes

Medication interactions

Your physician reviews all prescriptions, supplements, and over-the-counter medications during intake before anything is prescribed.

Safety

Safety & considerations

Compounded, not FDA-approved. Not appropriate with active malignancy. Disclose sleep and psychiatric medications during intake.

Regulatory status: Compounded. Evidence level: Limited. Eligibility, dosing, laboratory requirements, and follow-up care are determined exclusively by a licensed physician after review of your history.

Physician reviewed

Every protocol is approved by a licensed physician.

503A compounded

Prepared by licensed US compounding pharmacies.

Patient-specific Rx

Prescriptions are issued in your name only.

No membership

No concierge fee and no subscription to browse or begin.

Ready when you are

Find out what your body is actually asking for.

Fill out a short intake form and our care team will build a plan grounded in your labs — not a guess from a supplement aisle.